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Objective:

To report a case of reversible non-thrombocytopenic palpable

purpura associated with metoclopramide
Case Summary:

A 72 year old man was admitted for worsening palpable

purpura over a 2 day period. Two days prior to admission, metoclopramide,
10 mg orally three times daily, was started for a gastrointestinal condition.
Upon admission, all drugs were continued except metoclopramide. Over the
next 2 days, purpura began to resolve. Platelet count was within normal limits
upon admission and the patient suffered no serious consequences because of
the purpura.
Discussion: According to the available literature, reversible nonthrombocytopenic palpable purpura has not been previously reported with
metoclopramide. A search of Medline (1966 to 1998) and International
Pharmaceutical Abstracts (1970 to 1998) did not reveal a similar case.
Although a rechallenge of metoclopramide was not tried, this case appears to
demonstrate a temporal relationship between the initiation and discontinuation
of metoclopramide and the onset and resolution of symptoms. Similar cases
in the literature of this reaction have been reported with procainamide, which
is structurally similar to metoclopramide.
Conclusion: Metoclopramide may cause reversible non-thrombocytopenic
vascular-type palpable purpura. Discontinuation of the drug appeared to be
responsible for the resolution of symptoms.

Metoclopramide has a variety of indications including gastrointestinal
motility disorders, chemotherapy-induced vomiting, gastroesophageal reflux,
and diabetic gastroparesis. Classified as a benzamide, it is structurally similar
to procainamide, but lacks any significant local anesthetic or antiarrhythmic
actions. Its effects on the central nervous system and gastrointestinal system
are apparently mediated by dopaminergic blockade. Rash and
methemoglobinemia are rarely reported compared to the more common
adverse effects such as restlessness, drowsiness, diarrhea, and extrapyramidal
reactions.1
Although the manufacturer of metoclopramide1 has reported
maculopapular rashes, purpuric eruptions such as those displayed by this
patient have not been reported. This is a report of a patient who apparently
experienced reversible non-thrombocytopenic palpable purpura related to the
oral administration of metoclopramide.

Case Report: A 72 year old man presented to the emergency department
complaining of “patching” on his legs which had progressively worsened over
the past 2 days. He did not complain of pruritus or pain from the skin
eruption. Vital signs and temperature were within normal limits. Physical
examination revealed an extensive non-contiguous red patchy palpable skin
eruption covering approximately 80% of the patient’s lower extremities. The
skin eruptions did not blanche upon depression, thus purpura was suspected

rather than a local vasodilatory reaction. The patient had mild pedal edema,
presumed secondary to congestive heart failure, consistent with an exam
performed 2 days previously.
The patient was started on metoclopramide orally 10 mg three times
daily 2 days prior to admission for relief of abdominal pain, presumably
secondary to diabetic gastroparesis. Other outpatient medications included
dioxin 0.125 mg/day, albuterol 2 puffs every 4 hours, amlodipine 5 mg/day,
aspirin 325 mg/day, beclomethasone 2 puffs every 4 hours, furosemide 80 mg
two times daily, ipratropium bromide 2 puffs every 4 hours, insulin (70/30) 80
units every morning and 40 units every evening, and gemfibrozil 600 mg
twice daily. The patient reported no known drug allergies. Except for
metoclopramide, all other medications had been taken chronically for the last
year without significant changes.
The patient’s past medical history was significant for congestive heart
failure, type 1 diabetes, hypertension, chronic obstructive pulmonary disease
(requiring home oxygen), and gastroparesis apparently secondary to diabetes.
The patient had a 150 pack year history of smoking, but quit 2 years ago. In
addition, he drank 12 beers per day for 20 years, but states he quit 2 years ago
as well. Labs on admission were as follows: WBC = 8.8 x 103 cumm (4-10 x
103 cumm), platelets = 368 x 103/cumm (150-450 x103 cumm), hemoglobin =
11.2 g/dL (14-18 g/dL), hematocrit = 33.2% (36-54%), glucose = 197 mg/dL
(60-110 mg/dL), and serum creatinine = 2.9 mg/dL (0.7-1.4 mg/dL). All other
routine labs were within normal limits.

Metoclopramide was discontinued on admission to the hospital and all
other outpatient medications were continued. Over the next 2 days, there was
a significant reduction in the extent of purpura over the patient’s extremities.
No specific therapy was required to aid in the resolution of the reaction. A
platelet count was not obtained prior to discharge since the admission lab
value was within normal limits. The patient displayed no signs and symptoms
of bleeding and since the initial platelet count was within normal limits, no
other tests for coagulation were ordered. Purpura began to resolve shortly after
admission, thus dermatology was not consulted and a skin biopsy was not
obtained. The patient was not rechallenged with metoclopramide and since he
did not complain of abdominal pain, no other treatment was initiated. No
other complications were experienced during the patient’s 3 days of
hospitalization.

Discussion
Metoclopramide was first introduced in the 1960s as an antiemetic.
Since then, many adverse effects have been reported to the manufacturer and
documented in the literature. When Pinder et al reviewed the literature on the
use and pharmacologic properties of metoclopramide in 1976, the only
dermatologic effect noted was an urticarial or maculopapular rash.2 In 1982, a
case of thrombocytopenic purpura related to metoclopramide was reported as a
letter to the editor in the Spanish literature.3 A reaction associated with
metoclopramide similar to that experienced by our patient in this case report

was not found in either Medline (1966 to 1998) or International
Pharmaceutical Abstracts (1970 to 1998). Although causality is difficult to
prove, it is reasonable to postulate that the purpura experienced by this patient
was associated with metoclopramide. The timing of the purpura coincided
with the initiation of metoclopramide and resolution occurred shortly after its
discontinuation. All other medications had been used chronically for the past
year by the patient and were continued upon admission to this Veterans
Hospital. A similar literature search did not reveal an apparent relationship
between the patient’s reversible non-thrombocytopenic palpable purpuric
reaction and any of the other medications he was taking.
Purpura is characterized by extravasation of red blood cells into the
dermis, thus, unlike erythema and telangiectasias, it does not blanche with
pressure. Purpura can be divided into three main categories.4 The first
category is intravascular and is usually accompanied by nonpalpable purpura.
Aspirin and methyldopa have been associated with this type of purpura. The
second category is known as extravascular or miscellaneous and may be
palpable or nonpalpable. Possible etiologies of this category include toxins,
venoms, scurvy, and corticosteroids (usually reported as nonpalpable).5
Although the patient in this case report was using inhaled beclomethasone, a
topical corticosteroid, it is unlikely that this was the cause of his purpura as he
had been using it for over a year; reactions with corticosteroids usually present
as nonpalpable purpura; and systemic absorption is minimal. The third
category is termed vascular and is usually characterized by palpable purpura.

In fact, one of the most likely causes of palpable purpura is inflammatory
small-vessel vaculitis.6 This type of purely cutaneous vasculitis is often
associated with drugs such as penicillin, sulfonamides, and phenytoin.4
Symptoms may include pruritus, burning and, less often, pain, but the
presence or absence of these symptoms is not considered integral to the
diagnosis.4
This patient most likely had an inflammatory vascular cutaneous
reaction. The lack of thrombocytopenia, temporal association with a drug, and
palpable nature of the purpura further supports this description.
Procainamide, an antiarrhythmic agent, is classified as an alkaloid with
a substituted amide linkage. This structure is consistent with the benzamides,
notably metoclopramide. Structural similarities between different classes of
drugs may help explain similarities in adverse effect profiles. For instance,
procainamide was associated with a purpuric ecchymotic eruption in a 74 year
old male.7 This patient had a normal platelet count, but the thromboplastin
time was noted to be elevated. In a case series by Knox et al., urticarial
vasculitis was associated with procainamide therapy in a 70 year old male and
a 74 year old male.8 In the latter case, the rash began to resolve on day 3 after
discontinuing procainamide and in the former case, resolution occurred 4 days
after discontinuation. The mechanism of this procainamide adverse reaction is
not well understood. One might speculate that since metoclopramide and
procainamide are structurally similar, the reaction noted in our patient might
be expected based on similar reactions reported from procainamide.

This case report illustrates a previously unreported case of reversible
non-thrombocytopenic vascular-type palpable purpura. Clinicians may want
to be aware of structural similarities between drugs and drug classes when
evaluating previously undocumented reactions to identify and manage them
appropriately.
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